FDA-approved1,2Evidence: Smaller human trialsHormones · Sexual and reproductive health

Nafarelin1

Also called Synarel1,2

Key takeaway

Nafarelin is a lab-made ten-amino-acid analogue of gonadotropin-releasing hormone (GnRH) and the active ingredient in Synarel.1,2 Its U.S. label covers central precocious puberty in children and endometriosis in women 18 and older, for whom experience is limited to six months of treatment.1 In controlled studies described in the label, it relieved endometriosis symptoms about as well as danazol or leuprolide, but bone density fell during six months of treatment and recovered only partly.1

Nafarelin at a glance

What it isA synthetic decapeptide analogue of gonadotropin-releasing hormone that, used repeatedly, lowers the body’s production of sex hormones, according to the Synarel label.1
FDA statusFDA-approved. Drugs@FDA lists Synarel, NDA 019886, with an original approval date of February 13, 1990. The cited label has no boxed warning.1,2
Human evidenceControlled studies in endometriosis comparing it with danazol and with leuprolide, and clinical trials in children with central precocious puberty, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is nafarelin?

Nafarelin is a synthetic peptide of ten amino acids, an analogue of the natural gonadotropin-releasing hormone in which one amino acid is replaced by 3-(2-naphthyl)-D-alanine, according to the label.1

In the United States it is the active ingredient of Synarel, approved under NDA 019886, according to Drugs@FDA.2

How does nafarelin work?

The label states that nafarelin first stimulates the pituitary to release LH and FSH, briefly raising sex hormone production, and that repeated use then abolishes this stimulation, so tissues that depend on sex hormones become inactive.1

What do human studies show?

In controlled clinical studies in endometriosis, the label states that nafarelin was comparable to danazol in relieving pelvic pain, painful periods and painful intercourse and in shrinking endometrial implants, and a single controlled trial found it clinically comparable to leuprolide.1

After six months of treatment, vertebral bone density measured by CT fell by an average of 8.7%, with only partial recovery after treatment stopped, according to the label.1

In clinical trials in children with central precocious puberty, breast development stopped or regressed in 82% of girls and genital development in all boys, and the effects reversed in all 69 children with a year of follow-up after treatment, according to the label.1

What the evidence base contains

  • Controlled human trial Controlled clinical studies in women with endometriosis comparing nafarelin with danazol, and a controlled trial comparing it with leuprolide, described in the label without enrolment numbers.1
  • Small, short, or incompletely reported human study Clinical trials in children with central precocious puberty in which breast development stopped or regressed in 82% of girls, with one-year follow-up after treatment in 69 children, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is nafarelin FDA-approved?

Yes. Drugs@FDA lists Synarel, application NDA 019886, with an original approval date of February 13, 1990.2

The Synarel label cited here (DailyMed SPL version 23, published March 10, 2026) states that it is indicated for central precocious puberty in children of both sexes and for the management of endometriosis, and that experience in endometriosis is limited to women 18 and older treated for six months.1

The label has no boxed warning. It states that it must not be used in pregnancy, and it warns that depression may occur or worsen with GnRH agonists.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Nafarelin is not among them.3,4

Timeline

  1. FDA approves Synarel, NDA 019886, according to Drugs@FDA.2
  2. DailyMed publishes the Synarel label version cited on this page.1

What is still unknown?

The clinical meaning of smaller endometriosis lesions: the label states that it is not known, and that lesion staging does not necessarily match symptom severity.1

Its use in endometriosis beyond six months, which the label states experience does not cover.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Nafarelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Nafarelin are a bounded selection, not every registration or paper about Nafarelin. For the years before Nafarelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Nafarelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Nafarelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Synarel for central precocious puberty and endometriosis. Controlled studies described in the label found it comparable to danazol and leuprolide for endometriosis symptoms. Bone density fell during six months of treatment and recovered only partly.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Nafarelin?

FDA-approved as Synarel for central precocious puberty and endometriosis. Controlled studies described in the label found it comparable to danazol and leuprolide for endometriosis symptoms. Bone density fell during six months of treatment and recovered only partly.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
9
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin.↗Source date November 9, 2026
  2. Literature metadata · added November 16, 2026

    A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone.↗Source date November 2, 2019
  3. Literature metadata · added November 16, 2026

    A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol.↗Source date August 28, 2019

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Nafarelin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

28Selected dated records
32Connected citations
9Populated source years1990–2026
3/4Record lanes present

Registered human studies

Trial composition

2 of 2 selected trial records include at least one phase value; 2 of 2 include a status value in the retained structured contract.

PhasesNot applicable 1Phase 1 1Phase 2 1
Status at observationCompleted 2

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 24Clinical Trial 16Randomized Controlled Trial 10Comparative Study 8Research Support, Non-U.S. Gov't 8Multicenter Study 6Review 4Case Reports 3Controlled Clinical Trial 1English Abstract 1Letter 1Research Support, U.S. Gov't, Non-P.H.S. 1Research Support, U.S. Gov't, P.H.S. 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
28

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 28 dated records

Research hub

Explore the Nafarelin evidence record

Open all 28 records →
28Dated records
3Evidence types
28Cited public sources
9Source years

Change ledger

Recently changed for Nafarelin

Open all 28 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00034047

PeptideScanner retained ClinicalTrials.gov record NCT00034047 at 2026-11-16T01:35:57.709Z. Its registry update date was 2008-01-25, and PeptideScanner's reviewed identity mapping was nafarelin.

PeptideScanner change date
November 16, 2026
Cited source date
January 25, 2008
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02865681

PeptideScanner retained ClinicalTrials.gov record NCT02865681 at 2026-11-16T01:35:57.709Z. Its registry update date was 2019-03-19, and PeptideScanner's reviewed identity mapping was nafarelin.

PeptideScanner change date
November 16, 2026
Cited source date
March 19, 2019
Evidence lane
Clinical trials

Official-source collections

Source records for Nafarelin

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. [Some possibilities for application of "Pfizer" medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice].Akusherstvo i ginekologiia · 2007
  2. Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment.Journal of assisted reproduction and genetics · 2001 Jun
  3. [Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis].Ginekologia polska · 2001 May
Explore all selected literature →
ClinicalTrials.gov2

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT02865681Registry update March 19, 2019 · completed at observation
  2. NCT00034047Registry update January 25, 2008 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span February 13, 1990 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
  • U.S. Department of Health and Human Services3
Dated updates connected to this profile · 28

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin.↗

    PubMed lists PMID 2533526 in Clinical endocrinology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1989-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone.↗

    PubMed lists PMID 9209899 in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol.↗

    PubMed lists PMID 1834049 in The Australian & New Zealand journal of obstetrics & gynaecology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1991-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Iontophoresis of nafarelin across human skin in vitro.↗

    PubMed lists PMID 8860440 in Pharmaceutical research as Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study.↗

    PubMed lists PMID 9720832 in European journal of obstetrics, gynecology, and reproductive biology as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.↗

    PubMed lists PMID 1533376 in Fertility and sterility as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    A comparison of nafarelin acetate and danazol in the treatment of endometriosis.↗

    PubMed lists PMID 2140996 in Fertility and sterility as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1990-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis.↗

    PubMed lists PMID 9389816 in Fertility and sterility as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Nafarelin in the management of endometriosis: quality of life assessment.↗

    PubMed lists PMID 1531576 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1992-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Nafarelin in the treatment of pelvic pain caused by endometriosis.↗

    PubMed lists PMID 2137972 in American journal of obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Comparison of the pharmacology of nafarelin and danazol.↗

    PubMed lists PMID 2137975 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Nafarelin versus danazol in the treatment of endometriosis.↗

    PubMed lists PMID 2137976 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    SYNAREL (nafarelin acetate) nasal solution · SPL version 23 · published 2026-03-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: SYNAREL (nafarelin acetate), NDA 019886 · original approval February 13, 1990 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026